Search Videos and More
Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic SyndromeNew research shows stem cell transplant represents the best therapeutic approach for older individuals with myelodysplastic syndrome. Dana-Farber Cancer Institute's Corey Cutler, MD, MPH, FRCPC explains more.
Treatment for Adults with Acute Lymphoblastic LeukemiaMarlise Luskin, MD, MSCE, a leukemia specialist at Dana-Farber Cancer Institute describes treatment for adults with acute lymphoblastic leukemia (ALL). She explains treatment considerations for younger adults and older adults with ALL.
Triplet Therapy Shows Promise in Phase 2 Study in Chronic Lymphocytic LeukemiaDana-Farber researchers find that combining a BCL-2 inhibitor with two other targeted agents is active in previously untreated CLL patients.
FDA Approval Insights: Idecabtagene Vicleucel for Relapsed/Refractory Multiple MyelomaDr. Munshi discusses the significance of the FDA approval of ide-cel in relapsed/refractory multiple myeloma, data from the KarMMa trial, which served as the basis for the approval, and next steps for CAR T-cell therapy in the field.
Hematologic Malignancies CMEThe care of patients with hematologic malignancies is evolving rapidly. These video highlights will discuss new developments in the diagnosis and treatment of hematologic malignancies, as presented at the 2020 Annual Meeting of the American Society of Hematology (ASH).
Researchers Focus on How to Invigorate ‘Exhausted’ T-Cells in ImmunotherapyDespite the sometimes-dramatic success of new cancer immunotherapies like checkpoint inhibitor drugs and CAR T cells, thus far only a minority of patients have responded or gained long-lasting benefits.
In Landmark Study, an Arthritis Drug Appears to Prevent Deadly Acute Graft-versus-host Disease after Bone Marrow TransplantAn immune-suppressing drug normally used to treat rheumatoid arthritis could make bone marrow transplant safer, report researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center. In a Phase 2 multi-center trial, the drug abatacept (ORENCIA®) reduced rates of severe, acute graft-versus-host disease (GVHD) and boosted rates of survival without acute GVHD or relapse in patients with leukemia and other blood cancers.
First FDA Approval of CAR T-Cell Therapy for Multiple Myeloma Marks Milestone for PatientsThe Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers and physicians at Dana-Farber Cancer Institute.
Next Questions: Chronic Lymphocytic LeukemiaJennifer Brown, MD, PhD, shares about multiple treatments and drug therapies and how long patients can remain on them while determining the best outcomes.
Dana-Farber to Offer First CAR T-Cell Therapy for Indolent Follicular Lymphoma Following FDA ApprovalThe Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for indolent follicular lymphoma, a slow growing, non-Hodgkin lymphoma (NHL), represents a key advance for patients with relapsed or refractory forms of the disease. Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC) will be a certified treatment center for the therapy.
Break Through Cancer Launches Collaborative Model Across Top U.S. Research Institutions in Pursuit of Cancer CuresBreak Through Cancer today announced its formal launch as a public foundation designed to find new solutions to the most intractable challenges in cancer.